Cargando…

Programmed Death-Ligand 1 as a Regulator of Tumor Progression and Metastasis

Programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) immune checkpoint has long been implicated in modeling antitumor immunity; PD-1/PD-L1 axis inhibitors exert their antitumor effects by relieving PD-L1-mediated suppression on tumor-infiltrating T lymphocytes. However, recent st...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vathiotis, Ioannis A., Gomatou, Georgia, Stravopodis, Dimitrios J., Syrigos, Nikolaos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8160779/ https://www.ncbi.nlm.nih.gov/pubmed/34065396 http://dx.doi.org/10.3390/ijms22105383

Ejemplares similares

Tumor Dormancy: Implications for Invasion and Metastasis
por: Gomatou, Georgia, et al.
Publicado: (2021)

Osimertinib Resistance: Molecular Mechanisms and Emerging Treatment Options
por: Gomatou, Georgia, et al.
Publicado: (2023)

Emerging therapies in thymic epithelial tumors (Review)
por: Dapergola, Athina, et al.
Publicado: (2023)

Programmed Cell Death Protein 1 Axis Inhibition in Viral Infections: Clinical Data and Therapeutic Opportunities
por: Tsiakos, Konstantinos, et al.
Publicado: (2022)

Comparison of programmed death-ligand 1 protein expression between primary and metastatic lesions in patients with lung cancer
por: Moutafi, Myrto K, et al.
Publicado: (2021)

The Role of REV-ERB Receptors in Cancer Pathogenesis
por: Gomatou, Georgia, et al.
Publicado: (2023)

Evolving Treatment Landscape of HER2-mutant Non-Small Cell Lung Cancer: Trastuzumab Deruxtecan and Beyond
por: Vathiotis, Ioannis A., et al.
Publicado: (2023)

Assessment of Seroconversion after SARS-CoV-2 Vaccination in Patients with Lung Cancer
por: Trontzas, Ioannis P., et al.
Publicado: (2022)

The Role of Tinzaparin in Oncology
por: Dimakakos, Evangelos P., et al.
Publicado: (2017)

CD24: A Novel Target for Cancer Immunotherapy
por: Panagiotou, Emmanouil, et al.
Publicado: (2022)

New Insights into SARS-CoV-2 and Cancer Cross-Talk: Does a Novel Oncogenesis Driver Emerge?
por: Rapti, Vasiliki, et al.
Publicado: (2022)

Use of Programmed Death Receptor-1 and/or Programmed Death Ligand 1 Inhibitors for the Treatment of Brain Metastasis of Lung Cancer
por: Wang, Shiqiang, et al.
Publicado: (2020)

HER2 Aberrations in Non-Small Cell Lung Cancer: From Pathophysiology to Targeted Therapy
por: Vathiotis, Ioannis A., et al.
Publicado: (2021)

Crazy paving pattern as a rare radiological manifestation of peripheral T-cell lymphoma (PTCL) with lung involvement: A case report
por: Gomatou, Georgia, et al.
Publicado: (2018)

3-BrPA eliminates human bladder cancer cells with highly oncogenic signatures via engagement of specific death programs and perturbation of multiple signaling and metabolic determinants
por: Konstantakou, Eumorphia G., et al.
Publicado: (2015)

189P Assessment of seroconversion after SARS-CoV2 vaccination in patients with lung cancer
por: Trontzas, I.P., et al.
Publicado: (2022)

Comprehensive insights into the effects and regulatory mechanisms of immune cells expressing programmed death-1/programmed death ligand 1 in solid tumors
por: Liu, Min, et al.
Publicado: (2020)

Programmed cell death-1 and programmed cell death ligand-1 antibodies-induced dysthyroidism
por: Jaafar, Jaafar, et al.
Publicado: (2018)

Tinzaparin Safety in Patients With Cancer and Renal Impairment: A Systematic Review
por: Vathiotis, I. A., et al.
Publicado: (2021)

Baseline gene expression profiling determines long-term benefit to programmed cell death protein 1 axis blockade
por: Vathiotis, Ioannis A., et al.
Publicado: (2022)

Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations
por: Zerdes, Ioannis, et al.
Publicado: (2018)

Programmed Death 1 Ligand Expression in the Monocytes of Patients with Hepatocellular Carcinoma Depends on Tumor Progression
por: Asai, Akira, et al.
Publicado: (2020)

Vaccine-Related Autoimmune Hepatitis: Emerging Association with SARS-CoV-2 Vaccination or Coincidence?
por: Trontzas, Ioannis P., et al.
Publicado: (2022)

Antagonizing programmed death-1 and programmed death ligand-1 as a therapeutic approach for gastric cancer
por: Liu, Xiaojun, et al.
Publicado: (2016)

H1N1-Induced Venous Thromboembolic Events? Results of a Single-Institution Case Series
por: Dimakakos, Evangelos, et al.
Publicado: (2016)

Programmed death ligand-1/programmed death-1 inhibition therapy and programmed death ligand-1 expression in urothelial bladder carcinoma
por: Yu, Wei-Bo, et al.
Publicado: (2019)

Effect of baricitinib in regulating programmed death 1 and ligand programmed cell death ligand 1 through JAK/STAT pathway in psoriasis
por: Deepak, H. B., et al.
Publicado: (2022)

Regulation of Neuroinflammation through Programed Death-1/Programed Death Ligand Signaling in Neurological Disorders
por: Zhao, Shangfeng, et al.
Publicado: (2014)

Cbl-b Deficiency Mediates Resistance to Programmed Death-Ligand 1/Programmed Death-1 Regulation
por: Fujiwara, Mai, et al.
Publicado: (2017)

Programmed Cell Death-1/Programmed Death-ligand 1 Pathway: A New Target for Sepsis
por: Liu, Qiang, et al.
Publicado: (2017)

Recent Findings in the Regulation of Programmed Death Ligand 1 Expression
por: Shen, Xiangfeng, et al.
Publicado: (2019)

Significant Increase in Blood Pressure Following BNT162b2 mRNA COVID-19 Vaccination among Healthcare Workers: A Rare Event
por: Syrigos, Nikolaos, et al.
Publicado: (2022)

Clinical Response to Anti–Programmed Death 1 After Response and Subsequent Progression on Anti–Programmed Death Ligand 1 Therapy
por: Castellanos, Emily H., et al.
Publicado: (2017)

Programmed death ligand 1 (PD-L1) expression in parathyroid tumors
por: Pan, Boju, et al.
Publicado: (2019)

Targeting programmed death ligand 2/repulsive guidance molecule b pathway: a novel strategy to subdue tumor immunotherapy resistance to anti‐programmed death 1/programmed death ligand 1
por: Xiang, Yuancai, et al.
Publicado: (2023)

Programmed death ligand‐1 regulates angiogenesis and metastasis by participating in the c‐JUN/VEGFR2 signaling axis in ovarian cancer
por: Yang, Yufei, et al.
Publicado: (2021)

The role of the programmed cell death protein-1/programmed death-ligand 1 pathway, regulatory T cells and T helper 17 cells in tumor immunity: a narrative review
por: Zhang, Lanfang, et al.
Publicado: (2020)

Programmed death‐ligand 1 is a promising blood marker for predicting tumor progression and prognosis in patients with gastric cancer
por: Amatatsu, Masahiko, et al.
Publicado: (2018)

Regulation of ZEB1 Function and Molecular Associations in Tumor Progression and Metastasis
por: Perez-Oquendo, Mabel, et al.
Publicado: (2022)

Programmed death‐ligand 1 expression in swine chronic infections and enhancement of interleukin‐2 production via programmed death‐1/programmed death‐ligand 1 blockade
por: Ganbaatar, Otgontuya, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_vjls9jhvack81qr3r8jj1bp11r